NCT03517449 is the clinical trial number. In pMMR and all-comer patients, the LEN + pembro group showed clinically significant improvements in PFS2 as compared to TPC. Furthermore, the PFS2 rate at 6 months supported LEN + pembro over TPC in both the pMMR and all-comer populations (82.0 percent vs 74.8 percent) (81.7 percent vs 72.5 percent ). At the data cutoff date (October 26, 2020), 567 patients (LEN + pembro, n=282 TPC, n=285) had discontinued study treatment, and 315 patients (LEN + pembro, n=115 TPC, n=200) had received subsequent systemic anticancer therapy (Table), most commonly doxorubicin (n=58) in the LEN + pembro arm and paclitaxel (n=57) in the In the pMMR group (14.4 vs 9.8 mo HR 0.62, 95 percent CI 0.50–0.75) and the all-comer population (16.0 vs 9.5 mo HR 0.56, 95 percent CI 0.46–0.67), median PFS2 was longer in the LEN + pembro arm compared to the TPC arm. PFS2 (defined as the time from randomization to illness progression on next line of treatment or death, whichever came first) was evaluated by investigator assessment in the pMMR and all-comer populations in this prespecified exploratory analysis.Ĩ27 Pts (pMMR, n=697 dMMR, n=130) were randomly assigned to LEN + pembro (n=411) or TPC (n=416). MMR status (decided centrally) was used to stratify randomization patients with pMMR tumors were further classified by Eastern Cooperative Oncology Group performance status, geographic location, and history of pelvic radiotherapy. Patients with aEC and one prior platinum-based chemotherapy regimen (or up to two if one was given in a neoadjuvant/adjuvant context) were randomized (1:1) to LEN 20 mg orally QD + pembro 200 mg IV Q3W or TPC (doxorubicin at 60 mg/m2 IV Q3W or paclitaxel at 80 mg/m2 IV QW ). In this study, we looked at each arm's PFS on next-line treatment (PFS2). In Study 309/KEYNOTE-775, lenvatinib + pembrolizumab (L+P) demonstrated significant and clinically meaningful improvement in OS, PFS, and ORR compared with TPC. These findings were observed in both all-comer patients and patients with DNA mismatch repair proficient (pMMR) illness. In the multicenter, open-label, randomized, phase 3 Study 309/KEYNOTE-775, LEN + pembro demonstrated significant PFS and overall survival advantages, as well as a higher objective response rate compared to TPC in patients with aEC after systemic platinum-based treatment (Makker 2022, NEJM). In this video, he speaks about the ASCO 2022 Abstract - Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775 (309). Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.
#Keynote 775 how to#
How To Self Record An Interview and Presentationsīoost Your Earned Media starting at Just $60Įmbed (Iframe): Copy to Clipboard iFrame is not supported! Embed (Object): Copy to Clipboard Link (HTML): Copy to Clipboard Richard Woodman, MD #ASCO22 #OncoTwitter Phase 3 KEYNOTE-775 309 Study Link (BBCode): Copy to Clipboard Richard Woodman, MD #ASCO22 #OncoTwitter Phase 3 KEYNOTE-775 309 Study
0 kommentar(er)
